Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".
作者信息
Sohn Won
机构信息
Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2025 Jan;31(1):277-280. doi: 10.3350/cmh.2024.0823. Epub 2024 Oct 11.
Abstract
摘要
相似文献
1
Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".评估代谢功能障碍相关脂肪性肝病中晚期纤维化的重要工具：关于“振动控制瞬时弹性成像和磁共振弹性成像诊断非酒精性脂肪性肝病患者晚期肝纤维化的最佳截断值：一项系统评价和荟萃分析”的社论
Clin Mol Hepatol. 2025 Jan;31(1):277-280. doi: 10.3350/cmh.2024.0823. Epub 2024 Oct 11.
2
Correspondence to editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis".致关于“振动控制瞬时弹性成像和磁共振弹性成像在诊断非酒精性脂肪性肝病患者晚期肝纤维化中的最佳截断值：一项系统评价和荟萃分析”的社论的信函。
Clin Mol Hepatol. 2025 Jan;31(1):e61-e63. doi: 10.3350/cmh.2024.0878. Epub 2024 Oct 15.
3
Towards unification of liver stiffness measurement cutoffs: Editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".迈向肝硬度测量临界值的统一：关于“振动控制瞬时弹性成像和磁共振弹性成像在诊断非酒精性脂肪性肝病患者晚期肝纤维化中的最佳临界值：一项系统评价和荟萃分析”的社论
Clin Mol Hepatol. 2025 Jan;31(1):264-267. doi: 10.3350/cmh.2024.0766. Epub 2024 Sep 20.
4
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis.振动控制瞬时弹性成像和磁共振弹性成像在诊断非酒精性脂肪性肝病患者进展性肝纤维化中的最佳截断值：系统评价和荟萃分析。
Clin Mol Hepatol. 2024 Sep;30(Suppl):S117-S133. doi: 10.3350/cmh.2024.0392. Epub 2024 Aug 21.
5
A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.用于检测代谢功能障碍相关脂肪性肝病患者显著纤维化的非侵入性检测组合并不优于单独使用磁共振弹性成像。
Eur Radiol. 2024 Jun;34(6):3882-3888. doi: 10.1007/s00330-023-10441-5. Epub 2023 Nov 21.
6
Correspondence to editorial on "Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".致关于“振动控制瞬时弹性成像和磁共振弹性成像在诊断非酒精性脂肪性肝病患者晚期肝纤维化中的最佳截断值：一项系统评价和荟萃分析”的社论的信函
Clin Mol Hepatol. 2025 Jan;31(1):e52-e54. doi: 10.3350/cmh.2024.0815. Epub 2024 Sep 24.
7
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.弹性成像和磁共振成像在非酒精性脂肪性肝病患者中的诊断准确性：系统评价和荟萃分析。
J Hepatol. 2021 Oct;75(4):770-785. doi: 10.1016/j.jhep.2021.04.044. Epub 2021 May 13.
8
Evaluation of Liver Fibrosis through Noninvasive Tests in Steatotic Liver Disease.评估脂肪性肝病患者的肝纤维化：无创性检测手段。
Korean J Gastroenterol. 2024 Nov 25;84(5):215-222. doi: 10.4166/kjg.2024.103.
9
10
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease.非侵入性检查在代谢功能障碍相关脂肪性肝病预后评估中的作用
Clin Mol Hepatol. 2025 Feb;31(Suppl):S51-S75. doi: 10.3350/cmh.2024.0246. Epub 2024 Jun 27.
引用本文的文献
1
Impact of Short-Term Liraglutide Therapy on Non-Invasive Markers of Liver Fibrosis in Patients with MASLD.短期利拉鲁肽治疗对非酒精性脂肪性肝病合并代谢功能障碍患者肝纤维化无创指标的影响
Metabolites. 2025 Jul 31;15(8):510. doi: 10.3390/metabo15080510.
2
Correspondence to editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis".致关于“振动控制瞬时弹性成像和磁共振弹性成像在诊断非酒精性脂肪性肝病患者晚期肝纤维化中的最佳截断值：一项系统评价和荟萃分析”的社论的信函。
Clin Mol Hepatol. 2025 Jan;31(1):e61-e63. doi: 10.3350/cmh.2024.0878. Epub 2024 Oct 15.
本文引用的文献
1
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis.振动控制瞬时弹性成像和磁共振弹性成像在诊断非酒精性脂肪性肝病患者进展性肝纤维化中的最佳截断值：系统评价和荟萃分析。
Clin Mol Hepatol. 2024 Sep;30(Suppl):S117-S133. doi: 10.3350/cmh.2024.0392. Epub 2024 Aug 21.
2
Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).瑞美替隆：首个获美国食品药品监督管理局批准用于治疗非酒精性脂肪性肝炎（NASH）的药物。
Ann Pharmacother. 2025 Feb;59(2):162-173. doi: 10.1177/10600280241259528. Epub 2024 Jun 17.
3
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
4
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
5
Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.经活检证实的代谢相关脂肪性肝病的预后：CLIONE 研究的亚分析。
Clin Mol Hepatol. 2024 Apr;30(2):225-234. doi: 10.3350/cmh.2023.0515. Epub 2024 Jan 24.
6
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家组关于新的脂肪肝疾病命名的德尔菲共识声明。
J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.
7
Advances in the genetics of nonalcoholic fatty liver disease.非酒精性脂肪性肝病遗传学研究进展。
Curr Opin Gastroenterol. 2023 May 1;39(3):150-155. doi: 10.1097/MOG.0000000000000927. Epub 2023 Mar 1.
8
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的无创诊断和监测。
Lancet Gastroenterol Hepatol. 2023 Jul;8(7):660-670. doi: 10.1016/S2468-1253(23)00066-3. Epub 2023 Apr 13.
9
The growing burden of non-alcoholic fatty liver disease on mortality.非酒精性脂肪性肝病对死亡率的负担日益加重。
Clin Mol Hepatol. 2023 Apr;29(2):374-376. doi: 10.3350/cmh.2023.0084. Epub 2023 Mar 6.
10
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）的全球流行病学：系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
Zotero 插件